Navigation Links
Local therapy followed by treatment with EGFR TKI is well tolerated
Date:2/22/2013

DENVER Local therapy is not commonly utilized in metastatic lung cancer. Researchers at Memorial Sloan-Kettering Cancer Center investigated the efficacy of local therapy with continued EGFR TKI therapy specifically in patients with acquired resistance to EGFR TKIs. A recent study published in the March 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, found that EGFR- mutant lung cancers with acquired resistance to EGFR TKI therapy are amenable to local therapy to treat oligometastatic disease when used in conjunction with continued EGFR inhibition.

Eighteen patients were identified who received elective local therapy (surgical resection, radiofrequency ablation or radiation). Local therapy was well-tolerated, with 85 percent of the patients restarting TKI therapy within one month of local therapy. Local therapy with surgery, radiation, or radiofrequency ablation in selected patients is associated with a median overall survival of 41 months, a median time to progression of 10 months, and a median time to next systemic therapy of 22 months.

Researchers report that, "these remarkable outcomes in patients with EGFR mutant lung cancer are likely a result of multiple factors including the unique clinical course of this disease, patient selection, continued benefits of the TKI even after progression, and potential benefits of local therapy."

They also say, "While the patients reported here had long median overall survivals and delayted time to disease progression, there was a wide range of outcomes. Outcomes appeared to be best when the site of local therapy was the only known site of disease." Their experience suggests, "local therapy should be considered for patients with oligometastatic lung cancer with acquired resistance to EGFR TKI."


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1

Related biology news :

1. Chinese scientists discover evidence of giant pandas population history and local adaptation
2. Maple syrup, moose, and the local impacts of climate change
3. Greater effort needed to move local, fresh foods beyond privileged consumers
4. Global economic pressures trickle down to local landscape change, altering disease risk
5. In Fiji, marine protection gets local boost
6. Long-distance distress signal from periphery of injured nerve cells begins with locally made protein
7. First paternity study of southern right whales finds local fathers most successful
8. Managing biodiversity data from local government
9. New therapy for heart failure may enhance bodys stem cell response at cardiovascular injury site
10. Cell therapy a little more concrete thanks to VIB research
11. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... 5, 2014 – University of Utah engineers developed the ... jet fuel produce electricity without needing to ignite the ... power portable electronics, off-grid power and sensors. , A ... the American Chemical Society journal ACS Catalysis . ... chemical reaction between a fuel and an oxygen-rich source ...
(Date:11/4/2014)... 2014   3D ... Fuel3D , a developer of 3D scanning ... totaling $6.4 million (£4 million). This funding builds on the ... year and paves the way for the commercial launch of ... funding round was led by Chimera Partners and will be ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... CA Researchers from all over the world will be ... Department of Energy Joint Genome Institute 6th Annual Meeting, ... clean energy generation and the environment. Keynote speeches will ... Linear Accelerator Center, and microbial ecologist Terry Hazen of ...
... March 9, 2011 ActiveRx Rehabilitation , a ... working with senior adults, is now available to franchisees ... active aging. ActiveRx Development Company, Inc., based ... qualified operators interested in single or multi-location opportunities and ...
... - Hybrid plants with multiple genome copies show evidence of ... the genes of the other parent, even to the point ... Brian Dilkes, an assistant professor of genetics at Purdue University, ... California Davis and University of Southern California to study the ...
Cached Biology News:New Healthcare Franchise Opportunity Focuses on Treating Exploding Senior Population 2Study shows how plants sort and eliminate genes over millennia 2
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... patient has been dosed in its Phase 1 ... and cisplatin for the treatment of malignant pleural ...  Polaris Group is conducting clinical trials on ADI-PEG ... other agents, for the treatment of several other ...
(Date:11/18/2014)... -- Cord Blood Registry® (CBR®) announces that the ... Stem Cell Summit, the largest global meeting of stem cell ... Summit will be held December 3-5 at the Marriott Rivercenter ... The World Stem Cell Summit aims to ... convening the most prominent figures in the field to share ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring ... professor in the Regulatory Biology Laboratory at the Salk Institute, ... to an “off switch” for drug resistance in cancer. , ... research is making a global impact in the fight against ... host Cheryl K. Goodman, CEO of Social Global Mobile LLC, ...
(Date:11/18/2014)... 18, 2014 2014 Deep ... is professional and in-depth report on Polytetrahydrofuran ... information, including its definition, characterization, application, and ... This exploration covers the worldwide business investigation, ... examination covering macroeconomic environment & financial circumstance ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... in Cancer Stem Cell Biology Enhances, MacroGenics, Oncology Capabilities ... ... Platforms, ROCKVILLE, Md., July 17 MacroGenics, Inc., a ... and infectious diseases, today announced the,acquisition of Raven Biotechnologies, Inc., ...
... Arno Therapeutics,Inc. (OTC Bulletin Board: ARNI), today announced ... Board has changed from "LRRI.OB" to "ARNI.OB",effective July ... Therapeutics, Inc. is a clinical-stage biopharmaceutical company,that develops ... patients. Arno,s lead compound is AR-67, a novel, ...
... 17 Following intense,speculation in sections of ... Sankyo,Company, Limited (TSE: 4568.JP) ("Daiichi Sankyo") and ... the agreement,between Daiichi Sankyo, Ranbaxy and the ... is binding and final, subject to,regulatory approvals., ...
Cached Biology Technology:MacroGenics Acquires Raven Biotechnologies 2MacroGenics Acquires Raven Biotechnologies 3Arno Therapeutics Announces New Ticker Symbol 2Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation 2
Request Info...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Request Info...
Request Info...
Biology Products: